Ripretinib (DCC-2618) is an investigational, orally available switch control kinase inhibitor being developed for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors driven by tyrosine-protein kinase KIT (KIT) or platelet-derived growth factor alpha (PDGFRα) kinase. Ripretinib acts by forcing the activation loop (or activation "switch") of kinases into an inactive conformation and is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitor. Ripretinib is developed by the company Deciphera and is being investigated in phase 3 clinical trials for the treatment of GIST, ASM and other tumors.